NCPA Oral Antiviral Medication Participation

Report your involvement with the new COVID oral antiviral treatments and any changes in your status with these products over the coming months. You can access the tool here.

Report COVID-19 Therapeutics Billing Issues Here

• Pharmacist-prescribed paxlovid resources
• Billing for assessment by a pharmacist for Paxlovid treatment
• COVID-19 Antivirals Billing Information for NCPA Members
• NIH COVID-19 Treatment Guidelines
• COVID-19 Therapeutics information from the Assistant Secretary for Preparedness and Response (ASPR)
• COVID-19 Public Therapeutic Locator
  • only includes locations for Evusheld (monoclonal antibody), Molnupiravir (antiviral), and Paxlovid (antiviral)

Additional Information

• NCPA Summary of OSHA's Emergency Temporary Standard (June 2021)
• PREP Act 9th Amendment - Pharmacist ordering and administering COVID-19 therapeutics

COVID-19 Treatment Guidelines: Monoclonal Antibodies

• Important Updates on MABs from PHE.gov
• State/Territory-Coordinated Distribution of COVID-19 Monoclonal Antibody Therapeutics
• Resources for Healthcare Professionals from PHE.gov
• HHS Handout - Outpatient Cost and Coverage for Monoclonal Antibody Treatments: Frequently Asked Questions
• CE Opportunities:
  • CDC CE Webinar: Therapeutic Options to Prevent Severe COVID-19 in Immunocompromised People
  • Free CE training: Administering COVID-19 monoclonal antibodies
  • APhA CE: COVID-19 Monoclonal Antibody Assessment & Administration
• Monoclonal Antibody Products for COVID-19
• CMS sub-Q and infusion monoclonal antibodies billing

COVID-19 Treatment Guidelines: Oral Antivirals

FDA-authorized oral antivirals:

• Paxlovid (Pfizer)
• Molnupiravir (Merck)